Cullinan Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · -10.06%
- Market cap
- $661.54M
- 64.92M shares
- Filings
- 471
FY 2022−100.0% FY22 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2024N/M FY23 yoy
Q3 2026+6.4% FY25 yoy
- $661.54M
- —
- —
- 2.4×
- -26.57%
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2022 | 2022-12-31 | $0 | reported | |
| FY 2021 | 2021-12-31 | $18,943,000 | reported | |
| FY 2020 | 2020-12-31 | $0 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2020 | — | $6.57M | $6.57M | — | 29.83M sh | — | — |
Biological products, except diagnostic substances
Cullinan Therapeutics, Inc. is the 55th largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
AURAAura Biosciences, Inc.———$740.5MATTOAttovia Therapeutics, Inc.———$723.6MPRMEPrime Medicine, Inc.$4.6M55.3%4,342.4%$705.9MFDMT4D Molecular Therapeutics, Inc.$85.2M230,194.6%164.4%$682.1M
CGEMCullinan Therapeutics, Inc. (this company)———$661.5M
DNAGinkgo Bioworks Holdings, Inc.$170.2M25.1%183.8%$658.8MCADLCandel Therapeutics, Inc.———$658.2MSRZNSurrozen, Inc.$3.5M67.4%6,960.8%$605.8MSANASana Biotechnology, Inc.———$599.3MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Cullinan Therapeutics, Inc. · CIK 1789972 · Engraved from SEC EDGAR